Bone Microcirculation After Extracorporeal Shock Wave Therapy

NCT ID: NCT02424084

Last Updated: 2023-02-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-03-31

Study Completion Date

2023-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In trauma surgery and hand surgery treatment strategies of none healing bone fractures aim at replacing pseudarthrosis by well vascularized bone and improving microcirculation. Although previous studies indicate that extracorporeal shock wave therapy (ESWT) can accelerate bone healing in case of non-union, only a few studies focused on the elucidation of its mechanisms of action. Therefore, the aim of this study is to evaluate the microcirculatory effects of extracorporeal shock wave therapy on scaphoid bones and metacarpal and metatarsal in a human in-vivo setting for the first time.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intact Scaphoid Bone Intact Metacarpal Bone Fractured Scaphoid Bone Fractured Metacarpal Bone

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intact scaphoid bone

Group A (n=20): Consent-capable male and female patients ≥18 years of age who have an intact scaphoid.

Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)

Group Type EXPERIMENTAL

Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)

Intervention Type DEVICE

Extracorporeal Shock Wave Therapy

Intact metacarpal bone

Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metacarpal bone.

Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)

Group Type EXPERIMENTAL

Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)

Intervention Type DEVICE

Extracorporeal Shock Wave Therapy

Fractured scaphoid bone

Group C (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured scaphoid.

Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)

Group Type EXPERIMENTAL

Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)

Intervention Type DEVICE

Extracorporeal Shock Wave Therapy

Fractured metacarpal bone

Group D (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured metacarpal bone.

Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)

Group Type EXPERIMENTAL

Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)

Intervention Type DEVICE

Extracorporeal Shock Wave Therapy

Intact metatarsal bone

Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metatarsal bone.

Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)

Group Type EXPERIMENTAL

Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)

Intervention Type DEVICE

Extracorporeal Shock Wave Therapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)

Extracorporeal Shock Wave Therapy

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Group A (n=20): Consent-capable male and female patients ≥18 years of age who have an intact scaphoid.
* Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metacarpal bone.
* Group C (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured scaphoid.
* Group D (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured metacarpal bone.

Exclusion Criteria

* below 18 years of age
* scar tissue above scaphoid or metacarpal bone
* osteoporosis or comparable bone disease
* medication that influences bones
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital Schleswig-Holstein

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Tobias Kisch

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tobias Kisch, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital Schleswig-Holstein

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Schleswig-Holstein

Lübeck, Schleswig-Holstein, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

14-266-4

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.